Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled iloprost added to sildenafil for pulmonary arterial hypertension
2005-006192-13Phase 3Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Mar 2006
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing Inhaled iloprost plus sildenafil with Inhaled placebo plus sildenafil (2 arms). Primary endpoint: Change from baseline in 6-minute walk distance at Week 16 measured after inhalation. Started Mar 2006; status: completed.
02
Drugs
iloprostsildenafil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2005-006192-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-006192-13.